Literature DB >> 16461184

Role of aldosterone in left ventricular hypertrophy in hypertension.

Kiyoshi Matsumura1, Koji Fujii, Hideyuki Oniki, Masayo Oka, Mitsuo Iida.   

Abstract

BACKGROUND: Aldosterone induces cardiac fibrosis in experimental animal models, but only limited information is available on the association between aldosterone and left ventricular (LV) hypertrophy in human beings. The aim of the present study was to determine the role of aldosterone in LV geometry and to investigate other types of target organ damage in hypertensive patients.
METHODS: A total of 25 patients with primary aldosteronism caused by Conn's adenoma, 29 patients with renovascular hypertension, and 29 patients with essential hypertension (EHT) were included in the present study. Echocardiographic examinations and 24-h ambulatory blood pressure (BP) monitoring were conducted in all subjects.
RESULTS: The mean 24-h systolic and diastolic BP in primary aldosteronism and renovascular hypertension were found to be comparable to those in EHT. However, LV mass index adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, body mass index, and duration of hypertension was significantly increased in the patients with primary aldosteronism and renovascular hypertension compared with values in patients with EHT (150.2 +/- 7.7, 142.3 +/- 7.2, and 115.2 +/- 7.2 g/m(2), respectively). Hypertensive organ damages, such as proteinuria and hypertensive retinopathy, were more pronounced in the patients with renovascular hypertension; however, LV hypertrophy was especially exaggerated in patients with primary aldosteronism.
CONCLUSIONS: These results indicate that aldosterone may induce LV hypertrophy in human beings as well as in experimental animals, and that angiotensin II and aldosterone may differentially participate in causing hypertensive target organ damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461184     DOI: 10.1016/j.amjhyper.2005.05.013

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  32 in total

Review 1.  Primary aldosteronism.

Authors:  Richard J Auchus; Fiemu E Nwariaku
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 2.  Mineralocorticoid antagonism and cardiac hypertrophy.

Authors:  Kohzo Nagata
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  CT mapping of the vertebral level of right adrenal vein.

Authors:  Christoph Degenhart; Hanna Strube; Matthias J Betz; Anna Pallauf; Martin Bidlingmaier; Evelyn Fischer; Martin Reincke; Maximilian F Reiser; Stefan Wirth
Journal:  Diagn Interv Radiol       Date:  2015 Jan-Feb       Impact factor: 2.630

4.  Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.

Authors:  Krishna Gaddam; Cecilia Corros; Eduardo Pimenta; Mustafa Ahmed; Thomas Denney; Inmaculada Aban; Seidu Inusah; Himanshu Gupta; Steven G Lloyd; Suzanne Oparil; Ahsan Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

5.  Stress Reduction in the Prevention of Left Ventricular Hypertrophy: A Randomized Controlled Trial of Transcendental Meditation and Health Education in Hypertensive African Americans.

Authors:  Robert H Schneider; Hector F Myers; Komal Marwaha; Maxwell A Rainforth; John W Salerno; Sanford I Nidich; Carolyn Gaylord-King; Charles N Alexander; Keith C Norris
Journal:  Ethn Dis       Date:  2019-10-17       Impact factor: 1.847

Review 6.  Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.

Authors:  Gregory L Hundemer
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

7.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

8.  Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.

Authors:  C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

9.  The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.

Authors:  Chin-Chi Kuo; Poojitha Balakrishnan; Yenh-Chen Hsein; Vin-Cent Wu; Shih-Chieh Jeff Chueh; Yung-Ming Chen; Kwan-Dun Wu; Ming-Jiuh Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-07-16       Impact factor: 1.636

10.  Salt-sensitive hypertension and cardiac hypertrophy in mice deficient in the ubiquitin ligase Nedd4-2.

Authors:  Peijun P Shi; Xiao R Cao; Eileen M Sweezer; Thomas S Kinney; Nathan R Williams; Russell F Husted; Ramesh Nair; Robert M Weiss; Roger A Williamson; Curt D Sigmund; Peter M Snyder; Olivier Staub; John B Stokes; Baoli Yang
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.